Table 1. Planned doses of Dox by cohort delivered in the phase 1 study of dose-escalated Dox in cycles 1–3 ABVD.
| |
Dose of Dox in mg m–2 in cycles: | |
||||
|---|---|---|---|---|---|---|
| Cohort | 1–3 | 4 | 5 | 6 | Total dose Dox (% of standard ABVD) | Dose intensity Dox cycles 1–3 as % of standard ABVD |
| 1 |
35 |
25 |
25 |
0 |
310 mg m–2 (103) |
140 |
| 2 |
45 |
25 |
0 |
0 |
330 mg m–2 (110) |
180 |
| 3 |
55 |
0 |
0 |
0 |
330 mg m–2 (110) |
220 |
| 4 | 65 | 0 | 0 | 0 | 390 mg m–2 (130) | 260 |
Abbreviations: ABVD=doxorubicin, bleomycin, vinblastine, dacarbazine; Dox=doxorubicin.
Dose intensity in cycles 1–3 and cumulative dose over 6 cycles relative to standard ABVD are also shown.